S2423
Physics - Radiomics, functional and biological imaging, and outcome prediction
ESTRO 2026
Persson 18,19 , Jörgen Olofsson 20 , Per Bergström 20 , Hans- Olov Rosenbrand 21 , Britta Lödén 21 , André Haraldsson 22 , Silke Engelholm 22 , Eva Onjukka 1,2 , Karin Lindberg 2,7 1 Department of Nuclear Medicine and Medical Physics, Section of Radiotherapy Physics and Engineering, Karolinska University Hospital, Stockholm, Sweden. 2 Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. 3 Department of Oncology, Section of Radiotherapy, Karolinska University Hospital, Stockholm, Sweden. 4 Laboratory of Radiation Physics, Odense University Hospital, Odense, Denmark. 5 Department of Oncology, Odense University Hospital, Odense, Denmark. 6 Institute of Clinical Research, University of Southern Denmark, Odense, Denmark. 7 Theme Cancer, Section of Head, Neck, Lung and Skin Tumours, Karolinska University Hospital, Stockholm, Sweden. 8 Department of Radiology, Karolinska University Hospital, Stockholm, Sweden. 9 Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. 10 Department of Clinical Medicine, Faculty of Health Sciences, Aarhus University, Aarhus, Denmark. 11 Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. 12 Department of Medical Physics, Oslo University Hospital, Oslo, Norway. 13 Department of Oncology, Oslo University Hospital, Oslo, Norway. 14 Department of Therapeutic Radiation Physics, Sahlgrenska University Hospital, Gothenburg, Sweden. 15 Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 16 Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden. 17 Department of Oncology, Section of Radiotherapy, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark. 18 Department of Clinical Medicine, Faculty of Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 19 Department of Oncology, Copenhagen University Hospital – Herlev and Gentofte, Copenhagen, Denmark. 20 Department of Oncology, Northern Sweden University Hospital, Umeå, Sweden. 21 Department of Oncology, Central Hospital in Karlstad, Karlstad, Sweden. 22 Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden Purpose/Objective: Stereotactic body radiotherapy (SBRT) of central lung tumours carries a risk of high-grade toxicity, in particular bronchopulmonary bleeding. In our previous analyses of the expanded HILUS-cohort, bronchial tumour compression and dose to the main and intermediate bronchi (MIB) were identified as predictors of this fatal outcome [1]. In the current analysis we present the impact of the dose to large vessels on the risk of fatal bleedings.
on figures). Additionally, a small increase in T2* was found through treatment (+11%), suggesting, in line with HS evolution, a decrease in aggressiveness.
Conclusion: In this study, we demonstrated the feasibility of longitudinal qMRI follow-up on MR-Linac during prostate cancer SBRT. Although no significant evolution was demonstrated across patient population, it unveils possibilities for assessing in- treatment biomarkers with the aim of dose escalation or post-treatment follow-up to quantify the RT efficiency. References: [1] Chen et al. Evaluation of Hypoxia in Hepatocellular Carcinoma Using qMRI: Significances, Challenges, and Advances. JMRI. 2023[2] Mesny et al. Towards tumour hypoxia imaging: Incorporating relative oxygen extraction fraction mapping of prostate with multi- parametric quantitative MRI on a 1.5T MR-linac. JMRO. 2024[3] Surov et al. Correlation between ADC and cellularity is different in several tumors: a meta- analysis. Oncotarget. 2017 [4] Wu et al. Comparison of T2* mapping with DWI in the characterization of low- grade vs intermediate-grade and high-grade prostate cancer. BJR. 2016[5] Hompland et al. Combined MRI of Oxygen Consumption and Supply Reveals Tumor Hypoxia and Aggressiveness in Prostate Cancer Patients. Cancer Res. 2018 Keywords: MR-Linac, Quantitative MRI, Prostate Is dose to large thoracic vessels a predictor of fatal bleeding after SBRT of central lung tumours? – An analysis of the expanded HILUS-cohort Kristin Karlsson 1,2 , Jeehong Lee 1 , Daniel Alm 3 , Tine Bjørn Nielsen 4 , Lotte Holm Land 5,6 , Elias Lindbäck 1,2 , Sara Lindberg 2,7 , Vitali Grozman 8,9 , Karam Al-Jirf 2,7 , Lone Hoffmann 10,11 , Azza Khalil 10,11 , Christina Ramberg 12 , Lotte Victoria Rogg 13 , Ninni Drugge 14 , Jan Nyman 15,16 , Mirjana Josipovic 17,18 , Gitte Fredberg Digital Poster Highlight 1164
Made with FlippingBook - Share PDF online